Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ACY-241 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| ACY-241 combo with Ipi and Nivo | EXPERIMENTAL | ACY-241 in Combination with Ipilimumab and Nivolumab |
| ACY-241 in combination with Paclitaxel | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ACY-241 | DRUG | tablet |
| nivolumab | DRUG | infusion |
| ipilimumab | DRUG | infusion |
Inclusion Criteria: 1. Patients must have signed and dated an Institutional Review Board/Independent Ethics Committee -approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol-related procedures t...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ACY-241 is an investigational small molecule being studied for the treatment of advanced solid tumors and malignant melanoma. It has been evaluated in Phase 1 clinical trials, including one in combination with paclitaxel for advanced solid tumors and another with ipilimumab and nivolumab for malignant melanoma.
ACY-241 is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical research on this investigational oncology drug.
ACY-241 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. Two Phase 1 trials have been completed, one in advanced solid tumors and one in malignant melanoma.
ACY-241 has been studied in two completed Phase 1 trials. NCT02551185 evaluated ACY-241 in combination with paclitaxel in patients with advanced solid tumors, enrolling 20 participants. NCT02935790 evaluated ACY-241 in combination with ipilimumab and nivolumab in malignant melanoma, enrolling 1 participant.
ACY-241 is also referred to as ACY 241 in clinical trial titles. Both names refer to the same investigational drug being developed by Bristol-Myers Squibb for oncology indications.